Evaluation of HCV-related liver fibrosis post-successful DAA therapy
Open Access
- 28 June 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Egyptian Liver Journal
- Vol. 11 (1), 1-7
- https://doi.org/10.1186/s43066-021-00129-0
Abstract
Background The rapidly developing era of direct-acting antiviral regimens (DAAs) for more than one hepatitis C virus (HCV) genotype had certainly alleviated HCV burden all over the world. Liver fibrosis is the major dramatic complication of HCV infection, and its progression leads to cirrhosis, liver failure, and hepatocellular carcinoma. The impact of DAAs on liver fibrosis had been debatably evaluated with undetermined resolution. Main body The aim of this review is to accurately revise the effects of DAA regimens on liver fibrosis which can either be regression, progression, or non-significant association. Liver fibrosis regression is a genuine fact assured by many retrospective and prospective clinical studies. Evaluation could be concluded early post-therapy reflecting the dynamic nature of the process. Conclusions The ideal application of DAA regimens in treating HCV has to be accomplished with efficient non-invasive markers in differentiating proper fibrosis evaluation from necroinflammation consequences. Liver biopsy is the gold standard that visualizes the dynamic of fibrosis regression.Keywords
This publication has 68 references indexed in Scilit:
- The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosisJournal of Hepatology, 2012
- A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosisJournal of Hepatology, 2012
- Clinical evidence for the regression of liver fibrosisJournal of Hepatology, 2012
- Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patientsJournal of Hepatology, 2008
- Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regressionJournal of Hepatology, 2008
- Estimating progression to cirrhosis in chronic hepatitis C virus infectionJournal of Hepatology, 2001
- A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis CJournal of Hepatology, 2001
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CThe New England Journal of Medicine, 1998
- An algorithm for the grading of activity in chronic hepatitis CJournal of Hepatology, 1996
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995